Breaking Finance News

RBC Capital Markets disclosed Five Prime Therapeutics (NDAQ:FPRX), hiking its price target to $41.00 earlier today

Boasting a price of $35.86, Five Prime Therapeutics (NDAQ:FPRX) traded 2.48% higher on the day. With the last stock price close up 11.07% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Five Prime Therapeutics has recorded a 50-day average of $30.54 and a two hundred day average of $32.41. Volume of trade was down over the average, with 91,028 shares of FPRX changing hands under the typical 259,561

Reporting a potential upside of 0.14%, RBC Capital Markets bumped up the target of Five Prime Therapeutics (NDAQ:FPRX) to $41.00

Performance Chart

Five Prime Therapeutics (NDAQ:FPRX)

With a total market value of $0, Five Prime Therapeutics has with a one year low of $25.97 and a one year high of $60.98 .

A total of 6 equity analysts have released a ratings update on the company. 5 brokers rating the stock a strong buy, one analyst rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $45.83.

General Information About Five Prime Therapeutics (NDAQ:FPRX)

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.